The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 36 | — | 20.1x | Near average | |
Growth | 23 | -15.9% | 5.6% | Below average | |
Quality | 62 | 93.0% | 7.6% | Near average | |
Safety | 31 | 1.7x | 0.4x | Below average | |
Capital Return | 17 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
ProQR Therapeutics N.V. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy ProQR Therapeutics N.V. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The data shows complete stability in the average price target at 3.63 dollars over the past thirty days, with a wide gap (Dispersion) between the minimum (2 dollars) and maximum (5 dollars), reflecting a variance in fair value estimation despite a steady consensus. The current price (1.47 dollars) is trading at a significant discount to the average target, but the decrease in the number of active analysts to only two reduces the statistical reliability of this consensus.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.